Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001.
Authors
David Bing Zhen
University of Washington, Seattle, WA
David Bing Zhen , Martin Whittle , Paul S. Ritch , Howard S. Hochster , Andrew L. Coveler , Ben George , Andrew Eugene Hendifar , Tomislav Dragovich , Steven Green , Barbara Dion , Amy C. Stoll-D'Astice , Arthur Lee , Shelley M. Thorsen , Adam Rosenthal , Sunil R. Hingorani , E. Gabriela Chiorean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03634332
DOI
10.1200/JCO.2022.40.4_suppl.576
Abstract #
576
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).
First Author: E. Gabriela Chiorean
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Dong-Sheng Zhang
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI).
First Author: Farshid Dayyani